ARTICLE | Product R&D
Two firsts for Zika
Two mRNA vaccines show preclinical proof-of-concept in Zika
February 24, 2017 12:55 AM UTC
While companies are exploring a variety of traditional and emerging vaccine strategies to prevent Zika infection, two studies published this month suggest the newest modality - mRNA-based vaccines - could be competitive.
The studies, from Moderna Therapeutics Inc.’s Valera LLC spinout and the University of Pennsylvania, provide proof-of-concept data for two comparable, but not identical, RNA vaccines in preclinical models of Zika...